

Announcement No. 14/2010  
To NASDAQ OMX Copenhagen

Exiqon A/S  
Skelstedet 16  
2950 Vedbæk  
Denmark

Phone: +45 4566 0888  
Fax: +45 4566 1888  
exiqon@exiqon.com  
www.exiqon.com  
CVR/Tax Id: 18 98 44 31

29 June 2010

### **Registration of capital increase completed**

With reference to Announcement No. 11/2010, Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") is pleased to announce that the capital increase of 3,030,000 new shares with a nominal value of DKK 1 each was registered with the Danish Commerce and Companies Agency today.

Following registration of the 3,030,000 new shares with a nominal value of DKK 1 each, the nominal value of the share capital of Exiqon A/S amounts to DKK 33,335,249 divided into 33,335,249 shares with a nominal value of DKK 1 each.

Each share of nominally DKK 1 carries one vote at general meetings in the Company.

The new shares will be admitted to trading and official listing on NASDAQ OMX Copenhagen A/S on 1 July 2010 under the same ISIN code as the Company's existing shares.

Updated articles of association are attached.

### **Additional information**

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)  
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

### **About Exiqon**

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers (Exiqon Pharma Services). Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit [www.exiqon.com](http://www.exiqon.com).

